Bifunctional AR Degraders Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer and other diseases associated with aberrant androgen receptor (AR) regulation, such as prostate-specific antigen (PSA) protein, face challenges with drug resistance and side effects from oral androgen signaling pathway inhibitors, necessitating a need for targeted ubiquitination and degradation of AR.
Innovation Solution
Development of bifunctional compounds, specifically bifunctional compounds or proteolytic targeted chimeric (PROTAC) compounds that recruit endogenous proteins like AR to E3 ubiquitin ligases for targeted ubiquitination and degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral androgen signaling pathway inhibitors are used to treat prostate cancer, then AR function is inhibited, but drug resistance develops and side effects occur
Solution Approach 1:
The patent introduces a bifunctional PROTAC compound as an intermediary that mediates between the androgen receptor and the ubiquitin-proteasome system. The compound contains an AR-binding moiety, a link er, and an E3 ligase-binding moiety that work together to recruit the AR to the ubiquitin ligase, facilitating targeted degradation. This intermediary approach bypasses the need for direct inhibition, thereby avoiding traditional inhibitor resistance mechanisms and reducing side effects associated with androgen signaling blockade.
Solution Approach 2:
The patent changes the fundamental parameter of AR modulation from inhibition to degradation. By shifting from preventing AR function to eliminating AR protein entirely through ubiquitin-mediated degradation, the therapy achieves more complete and durable target suppression. This parameter change from functional inhibition to protein degradation overcomes drug resistance that develops with conventional inhibitors.
2Reliability
If current AR inhibition strategies are used, then AR function is suppressed, but the androgen receptor protein persists leading to drug resistance
Solution Approach 1:
The bifunctional PROTAC compound serves as a mediator that bridges the AR protein and the cellular ubiquitin-proteasome degradation machinery. The compound's design includes specific moieties that bind to both the AR and E3 ubiquitin ligase, positioning them in proximity to enable ubiquitin transfer and subsequent proteasomal degradation. This intermediary mechanism ensures complete protein elimination rather than mere functional suppression.
Solution Approach 2:
The patent extracts the AR protein from the system through targeted degradation. By recruiting the ubiquitin-proteasome system to specifically recognize and degrade the AR, the therapy removes the protein entirely from the cellular environment. This extraction approach eliminates the persistent AR protein that causes drug resistance in conventional therapies.
3Reliability
If AR is eliminated to treat prostate cancer, then tumorigenesis is addressed, but targeted degradation capability is required to avoid side effects
Solution Approach 1:
The PROTAC compound exhibits local quality through its modular design with distinct functional moieties. The AR-binding moiety provides specificity for the target protein, while the E3 ligase-binding moiety recruits the degradation machinery. The link er connects these moieties with specific properties that optimize the spatial arrangement for degradation. This localized functional differentiation enables precise targeting of AR while sparing other androgen receptors or proteins, thereby reducing side effects.
Solution Approach 2:
The bifunctional PROTAC acts as a targeted intermediary that mediates degradation specifically at the AR-proteasome interface. By requiring simultaneous binding to both AR and E3 ligase, the compound ensures highly selective degradation of the intended target. This intermediary mechanism avoids the non-specific effects of traditional inhibitors that block androgen signaling throughout the body, thereby reducing side effects while maintaining anti-tumor efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds effectively degrade the androgen receptor, providing a therapeutic benefit by reducing AR-driven tumorigenesis in prostate cancer and other AR-related diseases while minimizing side effects.
Implementation Method 1
The bifunctional compound allows the androgen receptor to be positioned adjacent to the ubiquitin ligase, so as to achieve the degradation or inhibition of the androgen receptor
Data Source
AI summary
The present invention relates to a bifunctional compound, a preparation method therefor, and a use thereof, wherein the bifunctional compound comprises an E3 ubiquitin ligase-binding moiety; a target protein-binding moiety that binds to an androgen receptor; and a linking moiety that links the E3 ubiquitin ligase-binding moiety and the target protein-binding moiety. The bifunctional compound of the present application allows the androgen receptor to be positioned adjacent to the ubiquitin ligase, so as to achieve the degradation or inhibition of the androgen receptor.